Advances in pharmacotherapy for primary biliary cholangitis
10.3969/j.issn.1001-5256.2017.06.037
- VernacularTitle:原发性胆汁性胆管炎的药物治疗进展
- Author:
Liujie LEI
;
Yingmei TANG
- Keywords:
liver cirrhosis,biliary;
therapy;
review
- From:
Journal of Clinical Hepatology
2017;33(6):1188-1191
- CountryChina
- Language:Chinese
-
Abstract:
The pathogenesis of primary biliary cholangitis (PBC) remains unclear.Ursodeoxycholic acid (UDCA) is currently the only drug approved by the Food and Drag Administration for the treatment of PBC,but some patients have a poor response to UDCA.New therapies can be considered for these patients.This article reviews the advances in drugs for PBC,including 6or-ethyl-chenodeoxycholic acid,fibrates,budesonide,and biological agents,and points out that these drugs bring new hope for PBC patients,but large-scale clinical studies are needed to confirm the long-term efficacy and safety.
